Toggle navigation
About
About us
Management Team
Board of Directors
Advisory Board
R&D
Immuno-oncology
Technology
Collaborations
Publications
Posters
Clinical program
Partnering
Investors
Overview
The share
Shareholder information
Nomination committee
Largest shareholders
Financial calendar
Reports & Presentations
Financial Reports
Presentations
Information Document
Events
Analyst coverage
IR Contact
National Prospectus 2024
News
Press releases & other news
Subscribe
Contact
post@lytixbiopharma.com
News
news
Press releases & other news
Subscribe
Mar 21, 2016
A positive editorial discussion on LTX-315`s mode of action in the journal Cell Cycle
Positive editorial discussion in the Journal: Cell Cycle, focusing on LTX-315 as a cationic anticancer peptide (CAP) which is “CAPtivating immunity with necrosis”.
Read article
Back